Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.70 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | GRK2 | P25098 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
| ▸ | GRK3 | P35626 | 1/20 | 0.45 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042184 | 0.91 | SCD (0.60) | SCDKLKB1CHRM4ROCK2GRK2 | |
| SCHEMBL3046804 | 0.87 | SCD (0.54) | SCDKLKB1HDAC6NR1H2NR1H3 | |
| SCHEMBL3054068 | 0.83 | SCD (1.00) | SCDKLKB1HDAC6NPC1 | |
| SCHEMBL3046807 | 0.81 | SCD (0.47) | SCDCHRM4CSNK2A2KDRPLK1 | |
| SCHEMBL14162241 | 0.78 | SCD (0.45) | SCDCHRM4ROCK2GRK2POLB | |
| SCHEMBL3046627 | 0.78 | SCD (0.46) | SCDKLKB1HDAC6NR1H2NR1H3 | |
| SCHEMBL27785697 | 0.73 | HPGD (0.48) | SCDCHRM4POLBRAB9A | |
| SCHEMBL3053289 | 0.71 | HPGD (0.57) | SCDCHRM4HDAC6 | |
| SCHEMBL3454791 | 0.70 | KDM4E (0.48) | SCDCHRM4CCR1 | |
| SCHEMBL3046884 | 0.70 | TSHR (0.51) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885KLKB1 4206/4885CHRM4 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.